John Freund Biography and Net Worth



John G. Freund, M.D. founded Skyline Ventures, in October 1997 and served as a Managing Director of Skyline until 2023. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management. In November 1995, he co-founded Intuitive Surgical, Inc., and served on its board of directors until March 2000. In 1996, he co-founded Arixa Pharmaceuticals, Inc., and served as its CEO until it was acquired by Pfizer in October 2020. From 1988 to 1994, he held various positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988, he was at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. He serves on the board of directors of Collegium Pharmaceuticals, Inc., Sutro Biopharma, Inc., and SI-Bone, an orthopedic device company. He also serves on the boards of directors of fourteen U.S. registered investment funds managed by affiliates of Capital Group, Inc. He previously served on the boards of directors of Map Pharmaceuticals, Inc., MAKO Surgical Corp., Proteon Therapeutics, Inc., Tetraphase Pharmaceuticals, Inc., Concert Pharmaceuticals, Inc., and was Chairman of XenoPort, Inc. He is a member of the Advisory Board for the Harvard Business School Healthcare Initiative.

Dr. Freund received a B.A. in History from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School, where he was a Baker Scholar.

What is John Gordon Freund's net worth?

The estimated net worth of John Gordon Freund is at least $1.10 million as of August 8th, 2025. Dr. Freund owns 23,129 shares of Collegium Pharmaceutical stock worth more than $1,097,008 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Freund may own. Learn More about John Gordon Freund's net worth.

How do I contact John Gordon Freund?

The corporate mailing address for Dr. Freund and other Collegium Pharmaceutical executives is 100 Technology Center Drive, Stoughton MA, 02072. Collegium Pharmaceutical can also be reached via phone at (781) 713-3699 and via email at [email protected]. Learn More on John Gordon Freund's contact information.

Has John Gordon Freund been buying or selling shares of Collegium Pharmaceutical?

John Gordon Freund has not been actively trading shares of Collegium Pharmaceutical within the last three months. Most recently, John Gordon Freund sold 11,659 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $34.36, for a transaction totalling $400,603.24. Following the completion of the sale, the director now directly owns 23,129 shares of the company's stock, valued at $794,712.44. Learn More on John Gordon Freund's trading history.

Who are Collegium Pharmaceutical's active insiders?

Collegium Pharmaceutical's insider roster includes Garen Bohlin (Director), Joseph Ciaffoni (CEO), Joseph Ciaffoni (Pres), Scott Dreyer (EVP), John Freund (Director), Michael Heffernan (Director), Shirley Kuhlmann (EVP), Thomas Smith (EVP), Colleen Tupper (CFO), and Colleen Tupper (Exec. VP & CFO ). Learn More on Collegium Pharmaceutical's active insiders.

Are insiders buying or selling shares of Collegium Pharmaceutical?

During the last year, insiders at the specialty pharmaceutical company sold shares 14 times. They sold a total of 201,586 shares worth more than $6,745,824.04. The most recent insider tranaction occured on November, 6th when CFO Colleen Tupper sold 30,000 shares worth more than $1,215,900.00. Insiders at Collegium Pharmaceutical own 2.5% of the company. Learn More about insider trades at Collegium Pharmaceutical.

Information on this page was last updated on 11/6/2025.

John Gordon Freund Insider Trading History at Collegium Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/8/2025Sell11,659$34.36$400,603.2423,129View SEC Filing Icon  
6/9/2025Sell6,601$30.62$202,122.6270,658View SEC Filing Icon  
5/12/2015Buy150,000$12.00$1,800,000.00View SEC Filing Icon  
See Full Table

John Gordon Freund Buying and Selling Activity at Collegium Pharmaceutical

This chart shows John Gordon Freund's buying and selling at Collegium Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Collegium Pharmaceutical Company Overview

Collegium Pharmaceutical logo
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Read More

Today's Range

Now: $47.43
Low: $47.00
High: $47.74

50 Day Range

MA: $39.09
Low: $32.04
High: $47.85

2 Week Range

Now: $47.43
Low: $23.23
High: $48.37

Volume

270,066 shs

Average Volume

654,743 shs

Market Capitalization

$1.50 billion

P/E Ratio

29.46

Dividend Yield

N/A

Beta

0.61